Heidelberg Pharma AG
Clinical-stage biopharma developing Amanitin-based ADCs for targeted cancer therapies.
HPHA | F
Overview
Corporate Details
- ISIN(s):
- DE000A11QVV0
- LEI:
- 391200E09XYBYITR1W32
- Country:
- Germany
- Address:
- Gregor-Mendel-Str. 22, 68526 Ladenburg
- Sector:
- Manufacturing
Description
Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-01-13 00:00 |
Hinweis auf Halbjahresfinanzbericht vom 01.12.2020 bis zum 31.05.2021
|
German | 5.8 KB | ||
| 2021-01-13 00:00 |
Hinweis auf Jahresfinanzbericht vom 01.12.2019 bis zum 30.11.2020
|
German | 5.8 KB | ||
| 2020-12-21 11:47 |
Heidelberg Pharma AG Receives Shareholder Loan Based on an Existing Financing C…
|
English | 8.6 KB | ||
| 2020-11-30 14:05 |
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.3 KB | ||
| 2020-11-12 15:01 |
Heidelberg Pharma will Present at German Equity Forum and Provides Update on Pa…
|
English | 15.4 KB | ||
| 2020-11-05 15:36 |
Heidelberg Pharma Announces Several Presentations of Research Results on ATAC T…
|
English | 16.7 KB | ||
| 2020-10-30 15:10 |
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.3 KB | ||
| 2020-10-13 00:00 |
Q3 statement / Q3 financial report 2019/2020
|
English | 160.2 KB | ||
| 2020-10-08 07:12 |
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of …
|
English | 32.2 KB | ||
| 2020-10-08 00:00 |
Quartalsfinanzbericht
|
German | 59.4 KB | ||
| 2020-09-29 11:03 |
Heidelberg Pharma AG Announces Adjustment of Guidance
|
English | 9.7 KB | ||
| 2020-09-14 07:16 |
Heidelberg Pharma Receives Milestone Payment from Partner Magenta
|
English | 9.3 KB | ||
| 2020-09-10 07:56 |
Heidelberg Pharma Announces Participation at Various Conferences
|
English | 10.5 KB | ||
| 2020-08-31 10:18 |
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.3 KB | ||
| 2020-07-22 14:15 |
Heidelberg Pharma AG: Annual General Meeting 2020 of Heidelberg Pharma Approves…
|
English | 11.9 KB |
Automate Your Workflow. Get a real-time feed of all Heidelberg Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Heidelberg Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Heidelberg Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-31 | Pahl, Prof. Dr. Andreas | Board | Other | None | N/A |
| 2023-12-18 | Pahl, Prof. Dr. Andreas | Board | Buy | None | 10,130.00 EUR |
| 2022-10-13 | 4H invest GmbH | Close relation | Other | None | 993,666.24 EUR |
| 2022-10-13 | Bohlini invest GmbH | Close relation | Other | None | 964,061.56 EUR |
| 2022-10-13 | MH-LT-Investments GmbH | Close relation | Other | None | 506,241.96 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 13,088.40 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 4,895.60 EUR |
| 2022-09-07 | Plate, Achim | Board | Buy | None | 30,869.92 EUR |
| 2022-09-06 | Kudlek, Dr. Birgit | Supervisory board | Other | None | 7,496.16 EUR |
| 2022-03-22 | 4H invest GmbH | Close relation | Other | None | N/A |
Peer Companies
